January 24, 2024
TransCelerate BioPharma Organized for Growth and Bringing New Innovation and Collaboration to the Biopharmaceutical R&D Community
Explore
Press Releases
October 13, 2022
TransCelerate BioPharma Appoints Janice Chang as New CEO
TransCelerate BioPharma Inc., today announced that Janice Chang, currently its Chief Operating Officer, has been appointed as TransCelerate’s new Chief Executive Officer. Janice will assume the role on January 1, 2023. Read more in the press release.
Explore
September 9, 2021
TransCelerate BioPharma Commences Collaborative Development of a Novel Digital Data Flow Solution for Study Start-Up
TransCelerate BioPharma Inc. (TransCelerate) announced today that it has commenced development on a reference implementation of a study definitions repository. The study definitions repository is a novel central component aimed at facilitating the exchange of structured study definitions across clinical systems using technical and data standards. For the full press release, please click here.
Explore
June 7, 2021
BioCelerate Continues to Help Improve Nonclinical Study Operations through Public Private Partnership with the FDA
BioCelerate, a subsidiary of TransCelerate BioPharma Inc. that focuses on identifying and developing pragmatic and tangible solutions to improve efficiencies in nonclinical research, today announced that it has released the first set of its solutions as part of its Public Private Partnership (PPP) with the U.S. Food & Drug Administration’s Center for Drug Evaluation and…
Explore
October 19, 2020
TransCelerate Launches New Initiatives to Support COVID-19 Research, R&D of Medicines, & More
DataCelerate® COVID-19 Module, Modernizing Critical Trial Conduct, Real World Data and Pharmacovigilance Agreements Optimization were all launched to support the continuity of clinical trials. We’ve also elected new Board leaders and added Bayer Pharmaceuticals as our newest member.
Explore
June 17, 2020
TransCelerate Expands COVID-19 Clinical Trial Data Sharing to Include All Biopharma Companies and BioMedical Research Institutions
TransCelerate BioPharma Inc., a non-profit collaboration comprised of 20 of the largest biopharmaceutical companies, today announced that it is expanding access to COVID-19-related patient-level clinical data sharing via DataCelerate® to non-member companies. In addition, TransCelerate will expand the type of data shared to include data from both the investigational product and control arms of COVID-19 clinical trials.…
Explore
April 15, 2020
TransCelerate BioPharma Member Companies Commit to Share COVID-19 Related Clinical Data via DataCelerate®
TransCelerate BioPharma Inc. announced that it will be utilizing its DataCelerate® platform to share Member Company control arm data from ongoing and planned COVID-19 clinical studies, as well as data from past studies in related diseases or patient populations. For the full press release click here.
Explore
June 10, 2019
BioCelerate Launches Two New Initiatives and Expands Membership
Explore
May 23, 2019
TransCelerate BioPharma Launches Three New Initiatives and Expands Membership
TransCelerate announced it has committed to an expansion of its clinical and drug safety portfolio, revealing three new initiatives: the Common Clinical Serious Adverse Events Fields Initiative, the Modernization of Data Analytics for Clinical Development Initiative and the Interpretation of Guidances and Regulations Initiative.
Explore
August 3, 2018
TransCelerate and BioCelerate Launch New Technology Platform to Enable R&D Data Sharing
DataCelerateTM Seamlessly Connects Clean, Converted Clinical & Preclinical Information within One Data Lake Solution.
Explore